Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria
- PMID: 26738565
- PMCID: PMC4704392
- DOI: 10.1186/s12936-015-1045-0
Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria
Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency exhibits considerable allelic heterogeneity which manifests with variable biochemical and clinical penetrance. It has long been thought that G6PD deficiency confers partial protection against severe malaria, however prior genetic association studies have disagreed with regard to the strength and specificity of a protective effect, which might reflect differences in the host genetic background, environmental influences, or in the specific clinical phenotypes considered.
Methods: A case-control association study of severe malaria was conducted in The Gambia, a region in West Africa where there is considerable allelic heterogeneity underlying expression of G6PD deficiency trait, evaluating the three major nonsynonymous polymorphisms known to be associated with enzyme deficiency (A968G, T542A, and C202T) in a cohort of 3836 controls and 2379 severe malaria cases.
Results: Each deficiency allele exhibited a similar trend toward protection against severe malaria overall (15-26% reduced risk); however, in stratifying severe malaria to two of its constituent clinical subphenotypes, severe malarial anaemia (SMA) and cerebral malaria (CM), the three deficiency alleles exhibited trends of opposing effect, with risk conferred to SMA and protection with respect to CM. To assess the overall effect of G6PD deficiency trait, deficiency alleles found across all three loci were pooled. G6PD deficiency trait was found to be significantly associated with protection from severe malaria overall (OR 0.83 [0.75-0.92], P = 0.0006), but this was limited to CM (OR 0.73 [0.61-0.87], P = 0.0005), with a trend toward increased risk for SMA, especially in fully-deficient individuals (OR 1.43 [0.99-2.08], P = 0.056). Sex-stratified testing largely comported with these results, with evidence suggesting that protection by G6PD deficiency trait is conferred to both males and females, though susceptibility to SMA may be restricted to fully-deficient male hemizygotes.
Conclusions: In a part of Africa where multiple alleles contribute to expression of G6PD deficiency trait, these findings clarify and extend previous work done in populations where a single variant predominates, and taken together suggest a causal role for G6PD deficiency trait itself with respect to severe malaria, with opposing effects seen on two major clinical subphenotypes.
Figures
Similar articles
-
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria.PLoS Med. 2007 Mar;4(3):e66. doi: 10.1371/journal.pmed.0040066. PLoS Med. 2007. PMID: 17355169 Free PMC article.
-
Glucose-6-phosphate dehydrogenase polymorphisms and susceptibility to mild malaria in Dogon and Fulani, Mali.Malar J. 2014 Jul 11;13:270. doi: 10.1186/1475-2875-13-270. Malar J. 2014. PMID: 25015414 Free PMC article.
-
Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility.Eur J Hum Genet. 2009 Aug;17(8):1080-5. doi: 10.1038/ejhg.2009.8. Epub 2009 Feb 18. Eur J Hum Genet. 2009. PMID: 19223928 Free PMC article.
-
Glucose-6-phosphate dehydrogenase deficiency and malaria.J Mol Med (Berl). 1998 Jul;76(8):581-8. doi: 10.1007/s001090050253. J Mol Med (Berl). 1998. PMID: 9694435 Review.
-
Glucose-6-phosphate dehydrogenase deficiency.Baillieres Best Pract Res Clin Haematol. 2000 Mar;13(1):21-38. doi: 10.1053/beha.1999.0055. Baillieres Best Pract Res Clin Haematol. 2000. PMID: 10916676 Review.
Cited by
-
Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.Pharm Res. 2018 Oct 15;35(12):237. doi: 10.1007/s11095-018-2517-z. Pharm Res. 2018. PMID: 30324329 Review.
-
Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia.Elife. 2017 Jan 9;6:e15085. doi: 10.7554/eLife.15085. Elife. 2017. PMID: 28067620 Free PMC article.
-
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.Am J Trop Med Hyg. 2017 Sep;97(3):702-711. doi: 10.4269/ajtmh.16-0779. Epub 2017 Jul 27. Am J Trop Med Hyg. 2017. PMID: 28749773 Free PMC article.
-
Glucose-6-phosphate dehydrogenase deficiency and reduced haemoglobin levels in African children with severe malaria.Malar J. 2016 Jul 7;15(1):346. doi: 10.1186/s12936-016-1396-1. Malar J. 2016. PMID: 27388012 Free PMC article.
-
Impairment of Invasion and Maturation and Decreased Selectivity of Plasmodium falciparum in G6PD Viangchan and Mahidol Variants.J Infect Dis. 2022 Apr 1;225(7):1238-1247. doi: 10.1093/infdis/jiab484. J Infect Dis. 2022. PMID: 34558618 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- 075491/Z/04/WT_/Wellcome Trust/United Kingdom
- G0600718/MRC_/Medical Research Council/United Kingdom
- 077383/Z/05/Z/WT_/Wellcome Trust/United Kingdom
- 090770/Z/09/Z/WT_/Wellcome Trust/United Kingdom
- 090770/WT_/Wellcome Trust/United Kingdom
- 090532/Z/09/Z/WT_/Wellcome Trust/United Kingdom
- MC_UP_A900_1118/MRC_/Medical Research Council/United Kingdom
- MR/M006212/1/MRC_/Medical Research Council/United Kingdom
- G19/9/MRC_/Medical Research Council/United Kingdom
- 077012/Z/05/Z/WT_/Wellcome Trust/United Kingdom
- ImNIH/Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
